Vertex Pharmaceuticals has been granted a patent for prodrug compounds of formula I, which have advantageous solubility and physicochemical properties. The patent also covers pharmaceutically acceptable compositions containing these compounds and their use in the treatment of various disorders, including pain. A process for preparing the compounds is also claimed. GlobalData’s report on Vertex Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vertex Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Vertex Pharmaceuticals's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Prodrug compounds with advantageous properties for treating disorders
A recently granted patent (Publication Number: US11773119B2) discloses a process for preparing a compound of formula I. The process involves treating a compound of formula B with K(PG1)2PO4 to obtain a compound of formula C, where X is P(O)(OH)2. The patent also includes various specific embodiments of the process, such as different substituents on the compounds and different values for X.
The process described in the patent involves transforming a compound of formula B into a compound of formula I. This transformation is achieved by treating the compound of formula B with K(PG1)2PO4, resulting in the formation of a compound of formula C. The compound of formula C has X as P(O)(OH)2. The patent further specifies different variations of the process, including different substituents on the compounds involved. For example, in one embodiment, R2 is H, R3 is CF3, R5 is CH3, R7 is F, and X is —PO(OH)2. In another embodiment, R2 is H, R3 is CF2CF3, R5 is OCH3, R7 is F, and X is —PO(OH)2.
The patent also includes claims for specific compounds of formula B and C. These compounds are selected from a group consisting of various specific structures. The compounds of formula B and C are important intermediates in the process for preparing the compound of formula I.
Overall, the granted patent (Publication Number: US11773119B2) discloses a process for preparing a compound of formula I by transforming a compound of formula B using K(PG1)2PO4. The patent provides various embodiments of the process, including different substituents on the compounds involved. Additionally, the patent claims specific compounds of formula B and C, which are important intermediates in the process. This patent could be valuable for researchers and companies working in the field of organic synthesis and pharmaceutical development, as it provides a novel and efficient method for synthesizing the compound of formula I.
To know more about GlobalData’s detailed insights on Vertex Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
